Acquired Lymphangiectasia Associated With Treatment for Preceding Malignant Neoplasm: A Retrospective Series of 73 Japanese Patients

we excluded the 2 patients with previously documented resistance from the analysis, we found that the trend for increasing ivermectin survival time remained significant (P=.006) (Table). Results from a single patient with recurrent CS and previously documented ivermectin resistance are of note (Figure). When this patient was treated again in 2006 with 3 doses of ivermectin (200 μg/ kg), no noticeable reduction in mite numbers was observed (unpublished observations). A significant increase in mite survival time was observed when mites collected after 8 days and 3 doses of ivermectin were compared with those collected prior to the commencement of ivermectin therapy (P=.003).